Abbott Labs Reports Material Agreements & New Financial Obligation

TL;DR

**Abbott Labs just reported new material agreements and financial obligations, but the filing is light on details.**

AI Summary

Abbott Laboratories filed an 8-K on January 29, 2024, indicating an "Entry into a Material Definitive Agreement," "Termination of a Material Definitive Agreement," and "Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement." While the filing confirms these events occurred on January 29, 2024, it does not provide specific details about the nature or financial impact of these agreements or obligations. This matters to investors because without specific details, it's impossible to assess the potential positive or negative financial implications for Abbott Laboratories' stock price or future performance.

Why It Matters

This filing signals significant corporate actions by Abbott Laboratories, but the lack of specific details prevents investors from understanding the potential financial impact on the company's valuation or future earnings.

Risk Assessment

Risk Level: medium — The filing indicates significant corporate actions (material agreements, new financial obligations) without providing any specific details, creating uncertainty for investors.

Analyst Insight

Investors should monitor future filings from Abbott Laboratories for specific details regarding these material agreements and financial obligations to assess their potential impact. Without further information, it's difficult to make an informed investment decision based solely on this 8-K.

Key Players & Entities

• ABBOTT LABORATORIES (company) — the registrant filing the 8-K
• January 29, 2024 (date) — date of the earliest event reported
• 100 Abbott Park Road (address) — principal executive offices of Abbott Laboratories
• 224-667-6100 (phone_number) — registrant's telephone number

Forward-Looking Statements

• Abbott Laboratories will file another 8-K or a 10-Q/K with more details about these material agreements and financial obligations. (Abbott Laboratories) — high confidence, target: Q1 2024 earnings report or subsequent filing

FAQ

Key Financial Figures

• $5 billion — Abbott with the ability to borrow up to $5 billion on an unsecured basis. Any borrowings u

Filing Documents

• tm244188d1_8k.htm (8-K) — 32KB
• 0001104659-24-007725.txt ( ) — 251KB
• abt-20240129.xsd (EX-101.SCH) — 3KB
• abt-20240129_def.xml (EX-101.DEF) — 28KB
• abt-20240129_lab.xml (EX-101.LAB) — 37KB
• abt-20240129_pre.xml (EX-101.PRE) — 26KB
• tm244188d1_8k_htm.xml (XML) — 5KB

01. Entry into a Material Definitive Agreement

Item 1.01. Entry into a Material Definitive Agreement. On January 29, 2024 (the " Effective Date "), Abbott Laboratories, an Illinois corporation (" Abbott "), entered into a Five Year Credit Agreement (the " Revolving Credit Agreement ") with the lenders from time to time party thereto and JPMorgan Chase Bank, N.A., as administrative agent. The Revolving Credit Agreement provides Abbott with the ability to borrow up to $5 billion on an unsecured basis. Any borrowings under the Revolving Credit Agreement will mature and be payable on the fifth anniversary of the Effective Date. As of the date of this Current Report on Form 8-K, there are no outstanding borrowings under the Revolving Credit Agreement. Abbott's borrowings under the Revolving Credit Agreement will bear interest, at Abbott's option, based on either a base rate or a SOFR rate, plus an applicable margin based on Abbott's credit ratings in effect from time to time. Abbott will also pay to the lenders under the Revolving Credit Agreement certain customary fees. The Revolving Credit Agreement contains representations and warranties and affirmative and negative covenants customary for unsecured financings of this type as well as customary events of default. The foregoing description of the Revolving Credit Agreement is qualified in its entirety by reference to the full text of the Revolving Credit Agreement, a copy of which will be filed with Abbott's annual report on Form 10-K for the period ending December 31, 2023. Some of the lenders under the Revolving Credit Agreement and/or their respective affiliates have in the past performed, and may in the future from time to time perform, investment banking, financial advisory, lending and/or commercial banking services, or other services for Abbott and its subsidiaries, for which they have received, and may in the future receive, customary compensation and expense reimbursement.

02. Termination of a Material Definitive Agreement

Item 1.02. Termination of a Material Definitive Agreement. In connection with its entry into the Revolving Credit Agreement, on the Effective Date Abbott terminated all commitments outstanding under the Five Year Credit Agreement, dated as of November 12, 2020 (as amended by that certain Amendment No. 1, dated as of May 12, 2023, the " Existing Credit Agreement "), among Abbott, the lenders from time to time party thereto and JPMorgan Chase Bank, N.A., as administrative agent. There were no outstanding borrowings under the Existing Credit Agreement at the time of its termination. The Existing Credit Agreement provided Abbott with the ability to borrow up to $5 billion on an unsecured basis. Absent termination, any borrowings under the Existing Credit Agreement would have matured and been payable on November 12, 2025. Abbott's borrowings under the Existing Credit Agreement bore interest, at Abbott's option, based on either a base rate or a SOFR rate, plus an applicable margin based on Abbott's credit ratings in effect from time to time. Some of the lenders under the Existing Credit Agreement and/or their respective affiliates have in the past performed, and may in the future from time to time perform, investment banking, financial advisory, lending and/or commercial banking services, or other services for Abbott and its subsidiaries, for which they have received, and may in the future receive, customary compensation and expense reimbursement.

03. Creation of a Direct Financial Obligation or an

Item 2.03. Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. The disclosure contained in Item 1.01 is incorporated in this Item 2.03 by reference. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ABBOTT LABORATORIES Date: January 29, 2024 By: /s/ Philip P. Boudreau Philip P. Boudreau Senior Vice President, Finance and Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR